Home Blog of Signal Transduction Others Others Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease

Lanthionine synthetase C-like 2 (LANCL2) therapeutics have gained increasing recognition as a novel treatment modality for a wide range of autoimmune diseases. Genetic ablation of LANCL2 in mice results in severe inflammatory phenotypes in inflammatory bowel disease (IBD) and lupus. Pharmacological activation of LANCL2 provides therapeutic efficacy in mouse models of intestinal inflammation, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and psoriasis. Mechanistically, LANCL2 activation enhances regulatory CD4 + T cell (Treg) responses and downregulates effector responses in the gut. The stability and suppressive capacities of Treg cells are enhanced by LANCL2 activation through engagement of immunoregulatory mechanisms that favor mitochondrial metabolism and amplify IL-2/CD25 signaling. Omilancor, the most advanced LANCL2 immunoregulatory therapeutic in late-stage clinical development, is a phase 3 ready, first-in-class, gut-restricted, oral, once-daily, small-molecule therapeutic in clinical development for the treatment of UC and CD. In this review, we discuss this novel mechanism of mucosal immunoregulation and how LANCL2-targeting therapeutics could help address the unmet clinical needs of patients with autoimmune diseases, starting with IBD.

 

Comments:

LANCL2 is indeed emerging as a promising target for treating autoimmune diseases due to its involvement in modulating immune responses. It's fascinating how its activation seems to enhance regulatory T cell responses while dampening inflammatory reactions.

The therapeutic potential of LANCL2 activation through drugs like Omilancor is exciting, especially in conditions like ulcerative colitis (UC) and Crohn's disease (CD), where the immune system is overly active in the gut.

This approach could significantly benefit patients with autoimmune disorders by specifically targeting mucosal immunoregulation, potentially offering a more targeted and effective treatment compared to conventional therapies.

The ability to enhance the stability and function of regulatory T cells while reducing inflammatory responses within the gut environment seems particularly promising. If this strategy continues to show positive results in clinical trials, it could represent a significant advancement in managing autoimmune conditions, potentially offering patients new avenues for more effective and tolerable treatments.

Related Products

Cat.No. Product Name Information
S6419 Omilancor (BT-11) Omilancor (BT-11) is an orally active lanthionine synthetase C-like 2 (LANCL2) binding compound for treating inflammatory bowel disease (IBD) (Kd value of 7.7 µM).

Related Targets

Others